No insider purchase over the last 90 days. The latest, by 邓学勤, was filed 30 May 2023.
Kexing Biopharm Co., Ltd.: what insiders have been doing
This page follows insider dealings at Kexing Biopharm Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. In the past year (5 November 2025 to 5 November 2026), 1 filing came from 1 insider.
There is no open-market purchase to report; the filings show 1 sale worth €5,621 by 1 insider. Biggest ticket of the year: €5,621, sold by 尚维 and made public on 20 August 2026.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 514 companies tracked on its exchange, the median is 2 filings; at 1 filing, this issuer sits below that mark. Looking back to 2023, when coverage begins, insiders filed 5 purchases and 2 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -7.6%Entry CN¥20.18 · Close at T+365 CN¥18.64
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,000 shares@ CN¥173.2982100.0% of flowA股XSHGSSE:273000001354166720
- 10,062,800 shares100.0% of flowA股XSHGSSE:173000009556952350
- 22,397 shares12.6% of flowA股XSHGSSE:173000006628061440Canonical exit: 28 Aug 2023 (T+90)
- 44,235 shares24.7% of flowA股XSHGSSE:173000006618638820Canonical exit: 23 Aug 2023 (T+90)
- 50,800 shares29.1% of flowA股XSHGSSE:173000006614201280Canonical exit: 21 Aug 2023 (T+90)
- 50,000 shares27.6% of flowA股XSHGSSE:173000006614257760Canonical exit: 20 Aug 2023 (T+90)
- 10,800 shares6.0% of flowA股XSHGSSE:173000006601808220Canonical exit: 15 Aug 2023 (T+90)
7 of 7 declarations
About Kexing Biopharm Co., Ltd.
科兴制药 is a company specializing in the health and pharmaceutical sector, listed on the XSHG market. It focuses on the development and production of vaccines and biopharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
